SPINRAZA PROCUREMENT

SPINRAZA can be ordered only directly through a specialty distributor (SD), CuraScript SD® for buy-and-bill, or from a specialty pharmacy (SP), Accredo®. They have extensive experience handling and distributing specialty pharmacy products for a variety of chronic and rare conditions. Ordering SPINRAZA follows a similar process as other products administered at your site of care. For assistance with the procurement process, please contact your Biogen representative.

SPINRAZA DISTRIBUTION MODEL

Illustrates the SP and SD processes and the steps for your practice or facility to take to obtain SPINRAZA.

SPECIALTY DISTRIBUTOR CHECKLIST

Tips to help obtain SPINRAZA through CuraScript Specialty Distributor, the designated SD for SPINRAZA.

SPECIALTY PHARMACY CHECKLIST

Tips to help obtain SPINRAZA through Accredo Specialty Pharmacy, the designated SP for SPINRAZA.

SPINRAZA REIMBURSEMENT

When a patient has been administered the SPINRAZA injection and/or a related service, your practice or facility may submit a claim to the patient’s insurance plan. Items included on your claim may depend on the site of care and the billing entity. Coding and billing recommendations may vary by health plan. Your practice or facility should check directly with the patient’s health plan(s) to verify specific coding and billing requirements. For assistance with SPINRAZA reimbursement, please contact your Biogen representative or SMA360° 1-844-4SPINRAZA (1-844-477-4672).

GUIDE TO SPINRAZA REIMBURSEMENT

A comprehensive guide to reimbursement considerations for SPINRAZA.

RELEVANT CODE AND SAMPLE CLAIM FORM GUIDE

Provides the relevant billing codes for SPINRAZA and instructions for completing claims forms.

J-CODE FLASHCARD

Contains information on how to use the permanent SPINRAZA J-Code.

OFFICE RESOURCES

Educational and practical resources to support your office in determining patient coverage and tracking communications with health plans.

REIMBURSEMENT TRACKING LOG

A log that your staff can use to help keep track of the reimbursement process for your patients receiving SPINRAZA.

COPAY REIMBURSEMENT FORM

A form for your staff to complete to help eligible patients receive reimbursement through the $0 Drug and $0 Procedure Copay Programs.

SPINRAZA PROCUREMENT

SPINRAZA can be ordered only directly through a specialty distributor (SD), CuraScript SD® for buy-and-bill, or from a specialty pharmacy (SP), Accredo® . They have extensive experience handling and distributing specialty pharmacy products for a variety of chronic and rare conditions. Ordering SPINRAZA follows a similar process as other products administered at your site of care. For assistance with the procurement process, please contact your Biogen representative.

SPINRAZA DISTRIBUTION MODEL

Illustrates the SP and SD processes and the steps for your practice or facility to take to obtain SPINRAZA.

SPECIALTY PHARMACY CHECKLIST

Tips to help obtain SPINRAZA through Accredo Specialty Pharmacy, the designated SP for SPINRAZA.

SPECIALTY DISTRIBUTOR CHECKLIST

Tips to help obtain SPINRAZA through CuraScript Specialty Distributor, the designated SD for SPINRAZA.

SPINRAZA REIMBURSEMENT

When a patient has been administered the SPINRAZA injection and/or a related service, your practice or facility may submit a claim to the patient’s insurance plan. Items included on your claim may depend on the site of care and the billing entity. Coding and billing recommendations may vary by health plan. Your practice or facility should check directly with the patient’s health plan(s) to verify specific coding and billing requirements. For assistance with SPINRAZA reimbursement, please contact your Biogen representative or SMA360° 1-844-4SPINRAZA (1-844-477-4672).

GUIDE TO SPINRAZA REIMBURSEMENT

A comprehensive guide to reimbursement considerations for SPINRAZA.

J-CODE FLASHCARD

Contains information on how to use the permanent SPINRAZA J-Code.

RELEVANT CODE AND SAMPLE CLAIM FORM GUIDE

Provides the relevant billing codes for SPINRAZA and instructions for completing claims forms.

OFFICE RESOURCES

Educational and practical resources to support your office in determining patient coverage and tracking communications with health plans.

REIMBURSEMENT TRACKING LOG

A log that your staff can use to help keep track of the reimbursement process for your patients receiving SPINRAZA.

COPAY REIMBURSEMENT FORM

A form for your staff to complete to help eligible patients receive reimbursement through the $0 Drug and $0 Procedure Copay Programs.

Key Icon

Please contact your Biogen representative to request printed copies of the above resources.

Photo of Lauren aged 20 years old with Type 3 SMA on a wheelchair talking to her friend
Lauren
age 20

Later-onset (Type 3) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease and duration of therapy.

INDICATION

SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

Coagulation abnormalities and thrombocytopenia, including acute severe thrombocytopenia, have been observed after administration of some antisense oligonucleotides. Patients may be at increased risk of bleeding complications.

In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 24 of 146 SPINRAZA-treated patients (16%) with high, normal, or unknown platelet count at baseline developed a platelet level below the lower limit of normal, compared to 10 of 72 sham-controlled patients (14%). Two SPINRAZA-treated patients developed platelet counts <50,000 cells per microliter, with the lowest level of 10,000 cells per microliter recorded on study day 28.

Renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. SPINRAZA is present in and excreted by the kidney. In the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 SPINRAZA-treated patients (58%) had elevated urine protein, compared to 22 of 65 sham-controlled patients (34%).

Laboratory testing and monitoring to assess safety should be conducted. Perform a platelet count, coagulation laboratory testing, and quantitative spot urine protein testing at baseline and prior to each dose of SPINRAZA and as clinically needed.

Severe hyponatremia was reported in an infant treated with SPINRAZA requiring salt supplementation for 14 months.

Cases of rash were reported in patients treated with SPINRAZA.

SPINRAZA may cause a reduction in growth as measured by height when administered to infants, as suggested by observations from the controlled study. It is unknown whether any effect of SPINRAZA on growth would be reversible with cessation of treatment.

The most common adverse reactions (≥20% of SPINRAZA-treated patients and ≥5% more frequently than in control patients) that occurred in the infantile-onset controlled study were lower respiratory infection and constipation. Serious adverse reactions of atelectasis were more frequent in SPINRAZA-treated patients (18%) than in control patients (10%). Because patients in this controlled study were infants, adverse reactions that are verbally reported could not be assessed. The most common adverse reactions that occurred in the later-onset controlled study were pyrexia, headache, vomiting, and back pain. Post-lumbar puncture syndrome has also been observed after the administration of SPINRAZA.

Please see full Prescribing Information for additional Important Safety Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.